Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
Jinyao Huang, Liang Zheng, Zicheng Sun, et al.
International Journal of Molecular Medicine (2022) Vol. 50, Iss. 4
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 22, pp. 2058-2070
Open Access | Times Cited: 342
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Mafalda Oliveira, Hope S. Rugo, Sacha J. Howell, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1231-1244
Closed Access | Times Cited: 12
Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer
Chenlin Liu, Fan Dong, Jiahui Sun, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Revenge Unraveling the Fortress: Exploring Anticancer Drug Resistance Mechanisms in BC for Enhanced Therapeutic Strategies
Ashi Mannan, Maneesh Mohan, Thakur Gurjeet Singh
Critical Reviews in Oncology/Hematology (2025), pp. 104707-104707
Closed Access | Times Cited: 1
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
Ioana-Miruna Stanciu, Andreea Paroşanu, Cristina Orlov‐Slavu, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 987-987
Open Access | Times Cited: 21
Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2− breast cancer: an umbrella review
Dongqing Pu, Debo Xu, Yue Wu, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 1
Open Access | Times Cited: 7
CD63+ cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20
Jiahui Sun, Ruoxin Du, Xiaoju Li, et al.
Cancer Letters (2024) Vol. 588, pp. 216747-216747
Open Access | Times Cited: 7
Autophagy and senescence facilitate the development of antiestrogen resistance in ER positive breast cancer
Michael K. McGrath, Ali Abolhassani, Luke Guy, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 6
Design, synthesis, and antitumor activity of benzimidazole derivatives as CDK4/6 inhibitors
Xiu Jun Wang, Xiao Hou, Luyao Zhang, et al.
Journal of Molecular Structure (2024) Vol. 1309, pp. 138189-138189
Closed Access | Times Cited: 6
Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
Rosalba Torrisi, Valentina Vaira, Laura Giordano, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1498-1498
Open Access | Times Cited: 4
Targeting STAT3 potentiates CDK4/6 inhibitors therapy in head and neck squamous cell carcinoma
Lin Dong, Chao Liu, Haoyang Sun, et al.
Cancer Letters (2024) Vol. 593, pp. 216956-216956
Closed Access | Times Cited: 4
Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis
Xiaogang Li, Chao Niu, Guoqiang Yi, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0305612-e0305612
Open Access | Times Cited: 4
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
H.S. Rugo, M. Oliveira, Sacha J. Howell, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103697-103697
Open Access | Times Cited: 4
Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling
Lulu Yang, Yajun Yue, Zhendong Wang, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 1, pp. 24-24
Open Access
Discovery of 2,4-Quinazolinedione Derivatives as LC3B Recruiters in the Facilitation of Protein Complex Degradations
Yanping Zeng, Jian Xiao, Shi Li, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117293-117293
Closed Access
Cleft Palate Induced by Mycophenolate Mofetil Is Associated with miR-4680-3p and let-7c-5p in Human Palate Cells
Hiroki Yoshioka, Hanane Horita, Yosuke Tsukiboshi, et al.
Non-Coding RNA (2025) Vol. 11, Iss. 1, pp. 12-12
Open Access
Arcyriaflavin A, a cyclin D1/CDK4 inhibitor, suppresses tumor growth, migration, and invasion of metastatic melanoma cells
Dokyeong Kim, Junseong Park, Yoon‐Seob Kim, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Discovery of novel oleanolic acid glycoside derivatives targeting PTP1B/PI3K/AKT signaling pathway for the treatment of breast cancer
Xiaoping Song, Lina Wang, Yao Liu, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108296-108296
Closed Access
CDK4/6 inhibitors upregulate cIAP1/2, and Smac mimetic LCL161 enhances their antitumor effects in cholangiocarcinoma cells
Pimchanok Menapree, Nattaya Duangthim, Apiwit Sae-Fung, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception
Jeanine Giarolla, Kelsey Holdaway, Maryam Nazari, et al.
Future Medicinal Chemistry (2025), pp. 1-21
Closed Access
Distinct allosteric networks in CDK4 and CDK6 in the cell cycle and in drug resistance
Wengang Zhang, D. Michael Bradburn, Gretchen Heidebrink, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment
Weijiao Chen, Xujie Zhuang, Yuanyuan Chen, et al.
Chinese Journal of Natural Medicines (2025) Vol. 23, Iss. 3, pp. 286-298
Closed Access
Distinct allosteric networks in CDK4 and CDK6 in the cell cycle and in drug resistance
Wengang Zhang, D. Michael Bradburn, Gretchen Heidebrink, et al.
Journal of Molecular Biology (2025), pp. 169121-169121
Open Access
Mechanisms of the JNK/p38 MAPK signaling pathway in drug resistance in ovarian cancer
Yuting Ma, Chan Li, Ying Shen, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top